Shares of Novavax, Inc. (NASDAQ:NVAX) have earned a consensus rating of “Hold” from the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $44.50.
NVAX has been the subject of several research analyst reports. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a report on Friday, February 1st. HC Wainwright initiated coverage on shares of Novavax in a research note on Monday, January 28th. They issued a “buy” rating and a $120.00 price target for the company. BidaskClub raised shares of Novavax from a “hold” rating to a “buy” rating in a research note on Wednesday, January 30th. B. Riley lowered their price target on shares of Novavax from $200.00 to $35.00 and set a “buy” rating for the company in a research note on Monday, March 4th. Finally, Cantor Fitzgerald reissued a “hold” rating and issued a $40.00 price target on shares of Novavax in a research note on Tuesday, January 29th.
In other news, Director Rachel K. King acquired 86,000 shares of the stock in a transaction dated Wednesday, March 27th. The stock was purchased at an average cost of $0.53 per share, with a total value of $45,580.00. Following the completion of the purchase, the director now owns 42,000 shares in the company, valued at approximately $22,260. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 3.30% of the company’s stock.
Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC raised its stake in Novavax by 52.6% in the 3rd quarter. MetLife Investment Advisors LLC now owns 284,027 shares of the biopharmaceutical company’s stock valued at $534,000 after purchasing an additional 97,901 shares during the last quarter. Opti Capital Management LP acquired a new stake in Novavax in the fourth quarter valued at approximately $39,000. Caption Management LLC purchased a new position in Novavax in the fourth quarter valued at approximately $1,085,000. Bank of New York Mellon Corp increased its stake in Novavax by 5.3% in the third quarter. Bank of New York Mellon Corp now owns 1,812,816 shares of the biopharmaceutical company’s stock valued at $3,408,000 after purchasing an additional 91,969 shares during the last quarter. Finally, Wedbush Securities Inc. raised its position in shares of Novavax by 102.1% in the 1st quarter. Wedbush Securities Inc. now owns 54,444 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 27,500 shares in the last quarter. 32.82% of the stock is owned by hedge funds and other institutional investors.
Shares of NVAX traded down $0.34 during mid-day trading on Friday, hitting $6.79. 129,466 shares of the company’s stock were exchanged, compared to its average volume of 631,298. The stock has a market capitalization of $135.20 million, a PE ratio of -0.67 and a beta of 1.98. Novavax has a fifty-two week low of $5.72 and a fifty-two week high of $51.60.
Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $0.20. The business had revenue of $3.98 million for the quarter, compared to analyst estimates of $4.80 million. During the same period in the prior year, the company posted ($2.80) EPS. On average, equities research analysts forecast that Novavax will post -7.31 EPS for the current year.
Novavax Company Profile
Novavax, Inc, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults.
Further Reading: P/E Growth (PEG)
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.